Biotech firm funded for rapid vaccine development with Covid-19 as first target
Through the use of a new technology, Evaxion Biotech is banking on developing vaccines against future pandemics in only 13 weeks time. A vaccine against Covid-19 could be the first in line, and the economic potential of the technology is enormous, says CBO/CMO.
BY ALBERT RØNNING-ANDERSSON, TRANSLATED BY DANIEL FRANK CHRISTENSEN & JONAS SAHL JØRGENSEN
Copehagen-based biotech firm Evaxion Biotech, founded in 2008, and which since has worked to develop the customized cancer treatment of the future, is now entering the market for the development of vaccines against pandemics such as the ongoing Covid-19.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
